MMP9 and lung cancer: Afatinib more effectively sensitizes lung cancer cells (Lewis lung carcinoma cells) to radiation and decreases metastasis by inhibiting phosphorylation of EGFR and HER2 and partly by decreasing matrix metalloproteinase 9 (MMP-9) production (56).